Cellular Neighborhoods in Chronic Skin Inflammation: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Chronic skin inflammation encompasses a range of dermatological disorders, including psoriasis, atopic dermatitis, and lichen planus, where intricate cellular interactions within the skin microenvironment—termed \"cellular neighborhoods\"—play a pivotal role in disease initiation, propagation, and persistence. This review synthesizes recent advances in our understanding of these cellular neighborhoods, evaluates their contribution to pathophysiology, and discusses clinical implications, diagnostics, and current as well as emerging treatment strategies. By integrating mechanistic insights from recent literature, the article highlights the necessity for neighborhood-focused approaches in both research and therapeutic targeting to improve outcomes for patients with chronic skin inflammatory diseases.

Introduction

Chronic skin inflammatory diseases are characterized by persistent, relapsing inflammation involving complex interactions among immune cells, resident skin cells, and stromal components. The concept of \"cellular neighborhoods\"—discrete microenvironments within tissue where specific cell types interact dynamically—has emerged from high-dimensional single-cell and spatial transcriptomics studies. Understanding the structure and function of these neighborhoods is crucial for unraveling the mechanisms underlying chronic skin inflammation and for developing targeted therapies. Clinicians and researchers alike are increasingly recognizing the need to move beyond individual cell-centric views to appreciate the spatial and functional relationships that shape disease phenotypes and responses to treatment.

Epidemiology / Disease Burden

Chronic inflammatory skin disorders affect millions globally, with psoriasis and atopic dermatitis being the most prevalent. Psoriasis impacts approximately 2-3% of the global population, while atopic dermatitis affects up to 20% of children and 3% of adults. These conditions are associated with significant morbidity, impaired quality of life, and increased risk of comorbidities such as cardiovascular disease and metabolic syndrome. The chronicity and relapsing nature of these disorders contribute to substantial healthcare utilization and economic burden. Epidemiological studies indicate rising incidence rates, particularly in urbanized and industrialized regions, pointing to the influence of environmental and lifestyle factors on disease prevalence and severity.

Pathophysiology

Chronic skin inflammation arises from dysregulated immune responses within the context of a permissive or altered skin barrier. Cellular neighborhoods are composed of diverse cell types, including keratinocytes, fibroblasts, dendritic cells, T cells (TH1, TH2, TH17, and regulatory subsets), macrophages, mast cells, and endothelial cells. Recent spatial omics technologies have revealed that the spatial arrangement and interaction of these cells—rather than their mere presence—determine the inflammatory milieu. For instance, proximity of TH17 cells to keratinocytes in psoriatic plaques facilitates IL-17-driven amplification loops, while in atopic dermatitis, TH2 cells cluster with Langerhans cells and eosinophils, fostering type 2 inflammation. These neighborhoods are dynamically regulated by cytokines (e.g., IL-4, IL-13, IL-17, TNF-α), chemokines, and cell-cell contact molecules, orchestrating chronicity and tissue remodeling. Crosstalk between immune and stromal cells also influences angiogenesis, fibrosis, and neuroinflammatory pathways, further perpetuating disease.

Risk Factors

Genetic predisposition, environmental exposures, and host factors all contribute to the formation and persistence of pathogenic cellular neighborhoods. Genome-wide association studies have identified risk alleles in genes regulating immune signaling (e.g., IL23R, FLG, TNF) and epidermal barrier integrity. Environmental triggers such as infections, trauma (Koebner phenomenon), allergens, and stress modulate the activation state and spatial organization of immune cells. Host factors, including age, gender, and microbiome composition, further shape the skin microenvironment and its propensity for chronic inflammation. Understanding these risk factors in the context of cellular neighborhoods is critical for personalized risk assessment and prevention strategies.

Clinical Features

The clinical manifestations of chronic skin inflammation are determined by the underlying cellular and molecular signatures of affected neighborhoods. Psoriasis typically presents with well-demarcated erythematous plaques with silvery scales, while atopic dermatitis features pruritic, eczematous lesions with lichenification in chronic stages. Lichen planus exhibits violaceous, polygonal papules with Wickham’s striae. The topographical distribution and morphology of lesions often reflect the localization and composition of pathogenic cellular neighborhoods. Pruritus, pain, and psychosocial distress are common, further contributing to disease burden. Complications such as superimposed infections and secondary systemic involvement may occur in severe or refractory cases.

Diagnosis

Diagnosis relies on clinical evaluation supplemented by histopathological examination and, increasingly, molecular profiling. Skin biopsies reveal architectural changes—such as acanthosis in psoriasis or spongiosis in atopic dermatitis—alongside immune cell infiltrates. Immunohistochemistry and in situ hybridization enable visualization of specific cell types and cytokine patterns within neighborhoods. Advanced spatial transcriptomics and multiplex imaging platforms now allow for mapping of cell-cell interactions at single-cell resolution, providing novel diagnostic and prognostic markers. Biomarkers derived from these studies, such as IL-17A or CCL20 expression, may guide subtype classification and therapeutic selection. Differential diagnosis includes infectious, neoplastic, and other inflammatory dermatoses requiring careful clinicopathological correlation.

Treatment & Management

Management of chronic skin inflammation involves a multimodal approach targeting immune dysregulation and restoration of barrier function. Topical corticosteroids, calcineurin inhibitors, and emollients remain first-line for mild to moderate disease. Systemic agents such as methotrexate, cyclosporine, and retinoids are reserved for extensive or refractory cases. For moderate to severe disease, biologics targeting TNF-α, IL-12/23, IL-17, and IL-4/13 pathways have revolutionized care, offering high efficacy and improved safety profiles. Phototherapy remains a valuable adjunct in select cases. Patient education, comorbidity management, and psychological support are critical components of holistic care. Therapeutic decisions should be individualized, considering disease severity, comorbidities, and patient preferences.

Recent Advances / Emerging Therapies

Recent scientific advances have illuminated the role of cellular neighborhoods in dictating therapeutic responses and resistance mechanisms. Spatial transcriptomics and multiplexed imaging have identified novel pathogenic cell clusters and signaling axes amenable to targeted intervention. Emerging therapies include JAK inhibitors, TYK2 inhibitors, and biologics with more selective cytokine blockade. Modulation of the skin microbiome and local immune microenvironment through probiotics, microbiome transplantation, or topical immune modulators is an active area of research. Personalized treatments based on neighborhood-specific biomarkers and real-time monitoring of cellular dynamics are on the horizon, promising to enhance efficacy and reduce adverse effects. Gene editing and cellular therapies are also being explored for refractory or genetically driven cases.

Guideline Recommendations

Current clinical guidelines emphasize evidence-based selection of therapies tailored to disease severity and patient characteristics. For psoriasis and atopic dermatitis, consensus guidelines advocate a stepwise approach starting with topical agents and escalating to phototherapy, conventional systemic drugs, and biologics as needed. Regular assessment of disease activity, comorbidities, and treatment tolerability is recommended. Guidelines increasingly recognize the importance of addressing psychological and quality-of-life aspects. The integration of biomarker-driven and spatially informed diagnostics is anticipated in future iterations of practice guidelines, reflecting the evolving understanding of cellular neighborhoods in disease pathogenesis and management.

Conclusion

Chronic skin inflammation is orchestrated by complex cellular neighborhoods whose structure and function dictate disease onset, progression, and therapeutic response. Advances in spatial biology are transforming our understanding of these microenvironments, offering new diagnostic and therapeutic avenues. Clinicians should integrate emerging scientific insights with guideline-based management to optimize outcomes for patients with chronic skin inflammatory diseases. Ongoing research into neighborhood-specific mechanisms and interventions holds promise for more precise, effective, and durable treatments in the future.